in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including Lilly’s CEO taking a role at Nike and Takeda’s illustrious global advisory board.
John Lechleiter, CEO of Eli Lilly, has been appointed to Nike’s board of directors. Nike believes that Lechleiter will help expand the company’s position “as the industry leader in innovation”.
Takeda has established a global advisory board to strengthen its corporate governance. The board will consist of members of Takeda’s current executive management and four external advisors.
Karen Katen, former vice chairman of Pfizer, Frank Morich, former CEO of Bayer HealthCare, Sidney Taurel, former CEO of Lilly and Tadataka Yamada, board member at GlaxoSmithKline (GSK), have all joined Takeda’s global governance group.
David Kappos has been nominated as Under Secretary of Commerce for Intellectual Property and Director of the US Patent and Trademark Office (USPTO).
BIO has welcomed Kappos’ nomination, praising his “true appreciation for industrial innovation”, and urged the Senate to move quickly so the USPTO has a confirmed leader.
Synta Pharmaceuticals has promoted Vojo Vukovic to senior vice president and chief medical officer. Prior to the promotion Vukovic was vice president, clinical research.
Vukovic has 17 years experience on oncology drug development at companies including Pfizer, Aventis Pasteur, Ortho Biotech, ILEX Oncology, and BioNumerik Pharmaceuticals.
Halozyme Therapeutics has appointed Michael Shepard as its vice president, discovery research. Shepard has more than 25 years experience in the biotech industry and led the team at Genentech that discovered Herceptin (trastuzumab).
Daniel Wilds has been appointed as executive chairman of Calcionics’ board of directors. Wilds has previously been CEO at SCOLR Pharma, Shiloov Biotechnologies, Adeza BioMedical, and Medisense.
He was also president of Travenol-Genentech, a joint venture between Baxter and Genentech and is currently on the board of directors of Helix BioMedix.